Skip to main content

Table 8 Evaluation of efficacy

From: Therapeutic effect of subcutaneous injection of low dose recombinant human granulocyte-macrophage colony-stimulating factor on pulmonary alveolar proteinosis

 

Cure

Improved

Invalidity or deterioration

Effective cases (Effective rate)

End of treatment(6 months)

1

16

3

17/20(85%)

End of follow-up (12 months)

0

14

3

14/17(82.35%)